(1-Hydroxy-2,5-dioxopyrrolidin-1-ium-1-yl) 3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-4-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (1-Hydroxy-2,5-dioxopyrrolidin-1-ium-1-yl) 3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-4-carboxylate
• 英文别名: (1-hydroxy-2,5-dioxopyrrolidin-1-ium-1-yl) 3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-4-carboxylate
• 化学式: C25H16NO10+
• 分子量: 490.4
• InChiKey: NNHGNTAXOLNOKK-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  36
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  157
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• HUMANIZED, MOUSE OR CHIMERIC ANTI-CD47 MONOCLONAL ANTIBODIES
  申请人：Forty Seven, Inc.

  公开号：EP3402820A1

  公开（公告）日：2018-11-21
• METHODS FOR IDENTIFYING ACTIVATING ANTIGEN RECEPTOR (ACAR)/INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR) PAIRS FOR USE IN CANCER THERAPIES
  申请人：ImmPACT-Bio Ltd.

  公开号：EP3856236A2

  公开（公告）日：2021-08-04
• Treatment Method
  申请人：KIRA BIOTECH PTY LIMITED

  公开号：US20200277396A1

  公开（公告）日：2020-09-03

  The present invention relates to a method of treating lymphoma in a subject, and more particularly, for treating Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL). The method comprises administering to the subject an effective amount of a CD83 binding protein. The invention also relates to methods for diagnosing and assessing lymphoma in a subject.
• [EN] HUMANIZED, MOUSE OR CHIMERIC ANTI-CD47 MONOCLONAL ANTIBODIES<br/>[FR] ANTICORPS MONOCLONAUX ANTI-CD47 HUMANISÉS, DE SOURIS OU CHIMÉRIQUES
  申请人：BLINK BIOMEDICAL SAS

  公开号：WO2017121771A1

  公开（公告）日：2017-07-20

  Humanized, mouse or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to human glycosylated and deglycosylated CD47 with an optimized Koff value, they disrupt the human CD47-SIRPα interaction, and find use in various therapeutic, preventive or diagnostic methods. The invention includes isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid and nucleotide sequences of the antibodies.
• [EN] METHODS FOR IDENTIFYING ACTIVATING ANTIGEN RECEPTOR (ACAR)/INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR) PAIRS FOR USE IN CANCER THERAPIES<br/>[FR] PROCÉDÉS POUR IDENTIFIER DES PAIRES RÉCEPTEUR ANTIGÉNIQUE ACTIVATEUR (ACAR)/RÉCEPTEUR ANTIGÉNIQUE CHIMÉRIQUE INHIBITEUR (ICAR) DESTINÉES À ÊTRE UTILISÉES EN CANCÉROTHÉRAPIES
  申请人：IMMPACT BIO LTD

  公开号：WO2020065406A2

  公开（公告）日：2020-04-02

  The present invention provides a method for identifying a target pair comprising i) an inhibitory chimeric antigen receptor (iCAR) or a protective chimeric antigen receptor (pCAR) capable of preventing or attenuating undesired activation of an effector immune cell, wherein the iCAR or pCAR target is directed to a target extracellular polymorphic epitope, and it) an activating chimeric antigen receptor (aCAR), wherein the aCAR is directed to a target non-polymorphic cell surface epitope of a protein, as well as methods of making and use of such pairs in the treatment of cancer.